Solvonis Therapeutics plc

Solvonis Therapeutics CEO Anthony Tennyson said the company's £1.3 million fundraising will support its CNS pipeline spanning SVN-001, SVN-002 and SVN-015. The funding will let Solvonis assess adding international sites to the Phase 3 programme for SVN-001, its severe alcohol use disorder treatment being trialled within the UK's NHS. On SVN-002, developed for moderate to severe alcohol use disorder in the US, the company is repurposing esketamine as an oral thin film via the FDA's 505(b)(2) pathway, building a scientific bridge to Johnson & Johnson's Spravato. The interview also covered SVN-015, Solvonis' proprietary compound targeting methamphetamine and cocaine addiction, with the US National Institute on Drug Abuse now funding further preclinical work following positive initial screening data.

Solvonis Therapeutics says new data supports its lead alcohol use disorder programme ahead of a planned Phase 2b trial, with CEO Anthony Tennyson noting the results could streamline development and open access to a market of around 15 million US adults. Tertiary Minerals has started its biggest-ever drilling programme in Zambia, aiming to define a maiden resource while testing for extensions and a potentially deeper sulphide system. CelLBxHealth is reshaping its strategy around cancer diagnostics and new pharma partnerships, with collaborations with AstraZeneca and AdventHealth potentially expanding clinical use of its Parsortix platform. Coinsilium Group says Bitcoin remains just one part of its growth story, as it also targets opportunities in AI, prediction markets and blockchain infrastructure. Eco Buildings Group has begun building its AI-enabled manufacturing platform in Albania, designed to boost efficiency and support global expansion. Frontier IP Group says a €211 million funding boost for portfolio company 2D Photonics marks a major milestone, with CEO Neil Crabb also highlighting progress across its AI, energy and healthcare investments.

Solvonis Therapeutics has reported positive bridging pharmacokinetic data for its SVN-002 programme, a key step toward a Phase 2b trial for moderate to severe alcohol use disorder in the US. CEO Anthony Tennyson said preclinical studies showed that sublingual and buccal delivery of esketamine achieved comparable exposure levels to intranasal administration, establishing the scientific bridge required by the FDA. The company is repurposing Johnson & Johnson's approved esketamine treatment Spravato via the FDA's 505(b)(2) pathway, targeting a market of around 15 million American adults with alcohol use disorder. Tennyson noted the data could support a narrower toxicology package and a faster, capital-efficient development timeline, with next steps including FDA discussions ahead of an IND application.

Eco Buildings Group has completed the second floor of its first apartment block in Albania, proving its prefab building system works at scale. The block of 18 apartments should bring in around €2.2 million in revenue upon completion, with five more blocks planned. Solvonis Therapeutics has cleared a key hurdle for its alcohol addiction treatment, showing it delivers the same drug levels as an approved depression medicine, clearing the path towards human trials within the next two years. Coinsilium Group has made a strategic investment in Predictive Labs, doubling down on prediction markets and AI, and also holds 50 million YELLOW tokens after a portfolio firm launched its trading platform. CelLBxHealth expects revenue of at least £2.1 million this year, up over 50%, after a year of deep restructuring, with new deals with AstraZeneca and AdventHealth backing up that growth target. NextEnergy Solar Fund says it can unlock up to £100 million of extra value through asset life extensions and a development pipeline, with generation coming in ahead of budget for the year to end March. Empire Metals has confirmed a huge high-grade titanium deposit in Western Australia, with some drill results topping 21% titanium dioxide, and an updated resource estimate due in the third quarter.